source
- STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trialLongevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.STAT · 1mo ago↗ source
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugFulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.BioPharma Dive · 1mo ago↗ source
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto settingAbivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The ReadoutSTAT · 1mo ago↗ source